Vaccine efficacy: Winning a battle (not war) against malaria

Lancet

Volumn 364, Issue 9443, 2004, Pages 1380-1383

  Van De Perre, Philippe ^a,b   Dedet, Jean Pierre ^a,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^c UMR 5093   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MODIFIED ANKARA MULTI EPITOPE THROMBOSPONDIN RELATED ADHESIVE PROTEIN; POLYPEPTIDE; SPOROZOITE VACCINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MALARIA; MALARIA FALCIPARUM; NOTE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

EID: 5644285250     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17235-8     Document Type: Note

References (13)

1. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present and future. Lancet Infect Dis. 4:2004;327-336
2. Greenwood B. Between hope and a hard place. Nature. 430:2004;926-927
3. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). Malaria transmission blocking vaccines: an ideal public good. 2000: http://www.who.int/tdr/publications/publications/pdf/tbv.pdf (accessed Oct 11, 2004).
4. Moorthy VS, Good MF, Hill AVS. Malaria vaccine developments. Lancet. 363:2004;150-156
5. Ballou WR, Arevalo-Herrera M, Carucci D, et al. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg. 71:(suppl 2):2004;239-247
6. Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 185:2002;1155-1164
7. Bojang KA, Milligan PJM, Pinder M, et al. Efficacy of RTS,S/ASO2A malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 358:2001;1927-1934
8. Kumar KA, Oliveira GA, Edelman R, Nardin E, Nussenzweig V. Quantitative Plasmodium sporozoite neutralization assay (TSNA). J Immunol Meth. 292:2004;157-164
9. Lyke KE, Dicko A, Kone A, et al. Incidence of severe Plasmodium falciparum malaria as primary endpoint for vaccine efficacy trials in Bandiagara, Mali. Vaccine. 22:2004;3169-3174
10. Ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg. 71:(suppl 2):2004;41-54
11. Hoffman S. Save the children. Nature. 430:2004;940-941
12. Nussenzweig RS. Immunoprophylaxis of malaria : sporozoïte-induced immunity. Adv Exp Med Biol. 93:1977;75-87
13. Moore M, Ewart S. Policy challenges in malaria vaccine introduction. Am J Trop Med Hyg. 71:(suppl 2):2004;248-252